Whitebox Advisors’s eFFECTOR Therapeutics, Inc. Warrant EFTRW Stock Holding History

Whitebox Advisors’s Portfolio EFTRW Stock Details EFTRW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-298,145	Closed	-$358	–	381
2024 Q2	$358	Hold	298,145	–	–	﹤0.01%	347
2024 Q1	$40.3K	Hold	298,145	–	–	﹤0.01%	172
2023 Q4	$44K	Hold	298,145	–	–	﹤0.01%	144
2023 Q3	$22.7K	Hold	298,145	–	–	﹤0.01%	168
2023 Q2	$51.7K	Hold	298,145	–	–	﹤0.01%	183
2023 Q1	$38.5K	Hold	298,145	–	–	﹤0.01%	280
2022 Q4	$48.8K	Hold	298,145	–	–	﹤0.01%	444
2022 Q3	$61K	Hold	298,145	–	–	﹤0.01%	563
2022 Q2	$75K	Hold	298,145	–	–	﹤0.01%	540
2022 Q1	$128K	Buy	+298,145	New	+$152K	﹤0.01%	580
2021 Q2	–	Sell	-33,333	Closed	-$26.9K	–	564
2021 Q1	$20K	Buy	+33,333	New	+$32.2K	﹤0.01%	357

Whitebox Advisors's EFTRW Position: Q3 2024 in Review

Whitebox Advisors sold out of eFFECTOR Therapeutics, Inc. Warrant (EFTRW) in Q3 2024, closing a stake of 298,145 shares — an estimated $358 sold.

Whitebox Advisors first reported a position in EFTRW in Q1 2021 and held it in 11 quarters. The position peaked at $128K in Q1 2022. 1 fund tracked by Wall St. Rank holds EFTRW as of Q3 2024.

Whitebox Advisors reported no remaining eFFECTOR Therapeutics, Inc. Warrant position as of Q3 2024 after selling out during the quarter.
Whitebox Advisors sold 298,145 eFFECTOR Therapeutics, Inc. Warrant shares in Q3 2024, an estimated $358.
Whitebox Advisors first reported a position in eFFECTOR Therapeutics, Inc. Warrant in Q1 2021 and held it in 11 quarters.
Whitebox Advisors's eFFECTOR Therapeutics, Inc. Warrant position peaked at $128K in Q1 2022.
1 fund tracked by Wall St. Rank held eFFECTOR Therapeutics, Inc. Warrant as of Q3 2024.

Based on Whitebox Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.